GlassScriptPhysician profile
Patrick Scott Jameson
NPI 1538707393
$20,293.42
in general payments reported to CMS, 2019-2025
29 companies · $4,528 in 2025
The $4,528 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,120 · 2022: $2,816 · 2023: $4,095 · 2024: $6,735 · 2025: $4,528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $800 · Education: $692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,865.53 |
| Consulting Fee | $800.00 |
| Education | $692.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,421.30 | 2021-2025 | |
| Janssen Biotech, INC. | $1,827.01 | 2021-2025 | Tremfya |
| Pfizer INC. | $1,634.11 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,343.11 | 2021-2025 | Ilumya, Odomzo, Absorica Ld |
| Ucb, INC. | $1,309.24 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $1,055.68 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $974.44 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $877.50 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Regeneron Healthcare Solutions, INC. | $874.30 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $847.67 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $777.30 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $674.60 | 2021-2025 | Otezla, Enbrel, Otezla |
| Arcutis Biotherapeutics, INC. | $670.35 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $641.35 | 2023-2024 | Vtama |
| Journey Medical Corporation | $500.71 | 2021-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $471.58 | 2021-2025 | |
| Incyte Corporation | $445.41 | 2022-2025 | Opzelura |
| Organon LLC | $189.70 | 2024-2025 | Vtama, Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.83 | 2022-2023 | Spevigo |
| Biofrontera INC. | $149.56 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Scientific Affairs, LLC | $149.07 | 2024 | Tremfya |
| Helsinn Therapeutics (U.S.), INC. | $96.98 | 2021-2023 | Valchlor |
| Botanix Sb INC | $66.43 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.14 | 2023-2024 | Cabtreo, Arazlo, Jublia |
| Vyne Pharmaceuticals INC. | $30.68 | 2021 | |
| Genentech USA, INC. | $18.44 | 2022 | |
| Blueprint Medicines Corporation | $17.31 | 2023 | Ayvakit |
| Mayne Pharma Commercial LLC | $16.69 | 2021 | |
| Biodermis LLC | $11.93 | 2025 | Pro-Sil, Epi-Derm, Biocorneum |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Jameson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.